Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 11/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30391927 | 0.93 | PI4KB (0.36) | ACLYPI4KBTSHRMAPK1KDM4E | |
| SCHEMBL21189735 | 0.93 | PI4KB (0.36) | ACLYPI4KBTSHRMAPK1KDM4E | |
| SCHEMBL21179450 | 0.91 | PI4KB (0.37) | ACLYPI4KBTSHRMAPK1KDM4E | |
| SCHEMBL21189578 | 0.85 | PI4KB (0.35) | ACLYPI4KBTSHRMAPK1KDM4E | |
| SCHEMBL30391794 | 0.85 | PI4KB (0.35) | ACLYPI4KBTSHRMAPK1KDM4E | |
| SCHEMBL21177603 | 0.84 | PI4KB (0.40) | ACLYPI4KBTSHRMAPK1KDM4E | |
| SCHEMBL21189737 | 0.81 | CRHR1 (0.32) | ACLYPI4KBTSHRMAPK1HSD17B10 | |
| SCHEMBL21177601 | 0.78 | PI4KB (0.50) | ACLYPI4KBKDM4EPI4KAMAPT | |
| SCHEMBL21177336 | 0.78 | PI4KB (0.50) | ACLYPI4KBKDM4EPI4KAMAPT | |
| SCHEMBL21179451 | 0.78 | PI4KB (0.39) | ACLYPI4KBTSHRMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649238-B2 | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-20230124394-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-20 | — | — | US | disclosed |
| US-20210387988-A1 | PI4KIIIbeta Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-12-16 | — | — | US | disclosed |
| EP-3740489-A1 | PI4KIIIBETA INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-11-25 | — | — | EP | disclosed |
| WO-2019141694-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124394-A1 | PI4KIIIBETA INHIBITORS | PI4KB, PI4K2B, PI4K2A | ACLY 2012/4885PI4KB 1/4885TSHR 3397/4885 |
| US-11649238-B2 | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors | PI4K2A, PI4K2B, PI4KA | ACLY 2344/4885PI4KB 4/4885TSHR 3228/4885 |
| US-20210387988-A1 | PI4KIIIbeta Inhibitors | PI4KB, PI4K2B, PI4K2A | ACLY 2023/4885PI4KB 1/4885TSHR 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.